{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:47:21Z","timestamp":1775177241416,"version":"3.50.1"},"reference-count":37,"publisher":"PAGEPress Publications","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Background: Cystitis is the most common clinical manifestation of urinary tract infection (UTI) in women.Aim: The current study intends to assess the effectiveness of CO2 micro-ablative vaginal laser therapy in the treatment of recurrent cystitis RC.Methods: A total of 75 women were divided into 2 Groups: Group 1 included 34 women (22 were menopausal women and 12 were non-menopausal women) with bacterial cystitis who were positive to urine culture analysis. The Group 2 included 41 women (34 were menopausal women and 7 were nonmenopausal women) with interstitial cystitis who were negative for urine culture analysis. Patients received three treatment sessions with a dual-wavelength (10600 nm\/1540 nm) laser system. A visual analog scale (VAS) evaluation, ranging from 0 to 10, was administered to assess baseline and post-laser treatment urinary symptoms associated with cystitis. Concerning IUS (stress urinary incontinence) and Urgency score measurements, a VAS ranging from 0 to 5 was used. The O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) was used as treatment outcome measures.Results: In both groups, a significant reduction in the average number of cystitis episodes after treatment was observed and the VAS scale showed a significant reduction in pre- and post-treatment symptoms. VAS results for patients\u2019 satisfaction and expectations showed positive outcomes revealing that more than 90% of patients were satisfied following the treatment.Conclusions: CO2 vaginal laser may represent an advantageous therapeutic approach to treating recurrent cystitis.<\/jats:p>","DOI":"10.4081\/aiua.2026.14671","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:18:13Z","timestamp":1772792293000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of CO&lt;sub&gt;2&lt;\/sub&gt; micro-ablative vaginal laser therapy in the treatment of recurrent cystitis"],"prefix":"10.4081","volume":"98","author":[{"given":"Maurizio","family":"Filippini","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ospedale di Stato, Cailungo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Sozzi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ospedale di Stato, Cailungo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"217730","doi-asserted-by":"crossref","unstructured":"1. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges, J. Infect. Dis. 2001; 183:S1-S4.","DOI":"10.1086\/318850"},{"key":"217731","doi-asserted-by":"crossref","unstructured":"2. Foxman B. Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. 2014; 28:1-13.","DOI":"10.1016\/j.idc.2013.09.003"},{"key":"217732","unstructured":"3. Naber KG, Tir\u00e1n-Saucedo J, Wagenlehner FME, RECAP group. Psychosocial burden of recurrent uncomplicated urinary tract infections. GMS Infect Dis. 2022; 10:Doc01."},{"key":"217733","doi-asserted-by":"crossref","unstructured":"4. McQuiston HJ, Dinesen MR, Nielsen ABS, et al. Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in Europe. Scand J Prim Health Care. 2013;31:235-40.","DOI":"10.3109\/02813432.2013.844410"},{"key":"217734","doi-asserted-by":"crossref","unstructured":"5. Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU Guideline. J Urol 2019;202:282-9.","DOI":"10.1097\/JU.0000000000000296"},{"key":"217735","unstructured":"6. Kodner CM, Gupton, E.K.T. Recurrent urinary tract infections in women: diagnosis and management. Am Fam Physician. 2010; 82:638-43."},{"key":"217736","unstructured":"7. Bitcoin C, Anderson K, Cox A. Treatment of interstitial. cystitis\/bladder pain syndrome: a contemporary review. EMJ 2020:91-99."},{"key":"217737","doi-asserted-by":"crossref","unstructured":"8. De Merwe V, Nordling J, Bouchelouche P, et al. diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: An ESSIC proposal. Joop P. Eur Urol. 2008:53; 60-7.","DOI":"10.1016\/j.eururo.2007.09.019"},{"key":"217738","doi-asserted-by":"crossref","unstructured":"9. Homma Y, Akiyama Y, Hwan KJ, et al. Definition change and update of clinical guidelines for interstitial cystitis and bladder pain syndrome. Low Urin Tract Symptoms. 2024; 16:e12532.","DOI":"10.1111\/luts.12532"},{"key":"217739","doi-asserted-by":"crossref","unstructured":"10. Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric 2019;22:242-249.","DOI":"10.1080\/13697137.2018.1551871"},{"key":"217740","doi-asserted-by":"crossref","unstructured":"11. Beerepoot M, Geerlings, S. Non-antibiotic prophylaxis for urinary tract infections. Pathogens 2016; 5:36.","DOI":"10.3390\/pathogens5020036"},{"key":"217741","doi-asserted-by":"crossref","unstructured":"12. Pabich WL, Fihn SD, Stamm WE, et al. Prevalence and determinants of vaginal flora alterations in postmenopausal women. J. Infect. Dis. 2003; 188:1054-1058.","DOI":"10.1086\/378203"},{"key":"217742","doi-asserted-by":"crossref","unstructured":"13. Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas 2016; 91:42-50.","DOI":"10.1016\/j.maturitas.2016.05.015"},{"key":"217743","doi-asserted-by":"crossref","unstructured":"14. Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol. Spectr. 2016; 4:37.","DOI":"10.1128\/microbiolspec.UTI-0025-2016"},{"key":"217744","doi-asserted-by":"crossref","unstructured":"15. Sekito T, Wada K, Ishii A, et al. Etiology of recurrent cystitis in postmenopausal women based on vaginal microbiota and the role of Lactobacillus vaginal suppository. Front Microbiol. 2023; 14:1187479.","DOI":"10.3389\/fmicb.2023.1187479"},{"key":"217745","doi-asserted-by":"crossref","unstructured":"16. Armelle J. Cystites r\u00e9cidivantes: Des moyens de pr\u00e9vention non m\u00e9dicamenteux. Progr\u00e8s Urol. 2017; 27:823-830.","DOI":"10.1016\/j.purol.2017.09.006"},{"key":"217746","doi-asserted-by":"crossref","unstructured":"17. Yoshimura N, Uno T, Sasaki M, et al. The O'Leary-Sant Interstitial Cystitis Symptom Index is a clinically useful indicator of treatment outcome in patients with interstitial cystitis\/bladder pain syndrome with Hunner lesions: A post hoc analysis of the Japanese phase III trial of KRP-116D, 50% dimethyl sulfoxide solution. Int J Urol. 2022; 29:289-","DOI":"10.1111\/iju.14765"},{"key":"217747","unstructured":"296."},{"key":"217748","doi-asserted-by":"crossref","unstructured":"18. Omi T, Numano K. The role of the CO2 laser and fractional CO2 laser in dermatology. Laser Ther. 2014; 23:49-60.","DOI":"10.5978\/islsm.14-RE-01"},{"key":"217749","doi-asserted-by":"crossref","unstructured":"19. Samuels JB, Garcia MA. Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women. Aesthetic Surg. J. 2019; 39: 83-93.","DOI":"10.1093\/asj\/sjy087"},{"key":"217750","doi-asserted-by":"crossref","unstructured":"20. Behnia-Willison F, Sarraf S, Miller J, et al. Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause. Eur J Obstet Gynecol Reprod Biol. 2017; 213:39-44.","DOI":"10.1016\/j.ejogrb.2017.03.036"},{"key":"217751","doi-asserted-by":"crossref","unstructured":"21. Gambacciani M, Torelli MG, Martella L, et al. Rationale and design for the vaginal erbium laser academy study (Velas): An international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. Climacteric. 2015;18:43-48.","DOI":"10.3109\/13697137.2015.1071608"},{"key":"217752","unstructured":"22. Bizjak-Ogrinc U, Sencar S, Vizintin Z. 3 years follow-up of pelvic organ prolapses treated with Er: YAG laser. Lasers Surg. Med. 2017;49:63."},{"key":"217753","unstructured":"23. Bizjak-Ogrinc U, Sentra S. Non-surgical minimally invasive Er: YAG Laser treatment for higher grade cystocele. Proceedings 38th Annual IUGA Meeting, Dublin; 2013."},{"key":"217754","doi-asserted-by":"crossref","unstructured":"24. Stefano S, Stavros A, Massimo C. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol. 2015; 27:504-508.","DOI":"10.1097\/GCO.0000000000000230"},{"key":"217755","doi-asserted-by":"crossref","unstructured":"25. Qi Y, Mo K, Wang A, He Y. Different effects of CO2 laser and estrogen treatment on vaginal mucosa microbiota and function in genitourinary syndrome of menopause patients. J Obstet Gynaecol Res. 2024;50:671-681.","DOI":"10.1111\/jog.15876"},{"key":"217756","unstructured":"26. De Vicente GJM, Guzm\u00e1n CT. Uso de la tecnolog\u00eda l\u00e1ser en urolog\u00eda funcional y uroginecolog\u00eda. Arch Esp Urol. 2020; 73:709-723."},{"key":"217757","unstructured":"27. Klap J, Campagne-Loiseau S, Berrogain N, et al. Vaginal LASER therapy for genito-urinary disorders: A systematic review and statement from the Committee for Female Urology and Pelviperineology of the French Association of Urology. Prog. Urol. 2021; 31:634-650."},{"key":"217758","doi-asserted-by":"crossref","unstructured":"28. Luvero D. The Efficacy of CO2 Vaginal laser in the treatment of recurrent,post-coital and interstitial cystitis: a multicentric prospective study. J Clin Med. 2024;13:3550.","DOI":"10.3390\/jcm13123550"},{"key":"217759","doi-asserted-by":"crossref","unstructured":"29. Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci 2015;30:429-36.","DOI":"10.1007\/s10103-014-1677-2"},{"key":"217760","doi-asserted-by":"crossref","unstructured":"30. Cui M, Honore P, Zhong C, et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. The Journal of Neuroscience. 2006; 26:9385-9393.","DOI":"10.1523\/JNEUROSCI.1246-06.2006"},{"key":"217761","doi-asserted-by":"crossref","unstructured":"31. Joseph RJ, et al. Finding a balance in the vaginal microbiome: how do we treat and prevent the occurrence of bacterial vaginosis? Antibiotics 2021; 10:719.","DOI":"10.3390\/antibiotics10060719"},{"key":"217762","doi-asserted-by":"crossref","unstructured":"32. Zhou X, Bent SJ, Schneider MG, et al. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. Microbiology (Reading) 2004; 150:2565-2573.","DOI":"10.1099\/mic.0.26905-0"},{"key":"217763","doi-asserted-by":"crossref","unstructured":"33. Auriemma RS, Scairati R, Del Vecchio G, et al. The vaginal microbiome: a long urogenital colonization throughout woman life. Front Cell Infect Microbiol 2021;11:686167.","DOI":"10.3389\/fcimb.2021.686167"},{"key":"217764","doi-asserted-by":"crossref","unstructured":"34. Song CH, Kim YH, Naskar M, et al. Lactobacillus crispatus limits bladder uropathogenic E. coli. infection by triggering a host type I interferon response. Proc Natl Acad Sci USA 2022;119:e2117904119.","DOI":"10.1073\/pnas.2117904119"},{"key":"217765","doi-asserted-by":"crossref","unstructured":"35. Biehl LM, Farowski F, Hilpert C, Nowag, et al. Longitudinal variability in the urinary microbiota of healthy premenopausal women and the relation to neighboring microbial communities: A pilot study. PLoS One. 2022; 17:e0262095.","DOI":"10.1371\/journal.pone.0262095"},{"key":"217766","doi-asserted-by":"crossref","unstructured":"36. Gilbert NM, O'Brien VP, Lewis AL. Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease. PLoS Pathog. 2017;13:e1006238.","DOI":"10.1371\/journal.ppat.1006238"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/14671\/13878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/14671\/13878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:48Z","timestamp":1775174448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/view\/14671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2026.14671","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}